You can buy or sell Motif Bio and other stocks, options, ETFs, and crypto commission-free!
Motif Bio plc ADRs, also called Motif Bio, is a clinical stage biopharmaceutical company which develops novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It pipeline of antibiotics includes iclaprim, and MTF-001, a preclinical program to design a dihydrofolate reductase inhibitor (DHFRi). Read More The company was founded on November 20, 2014 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Richard C. E. Morgan has tendered his resignation as Non-executive Chairman and is stepping down from the Board of Directors, effective immediately, to focus on other business commitments.
Stock Price, News, & Analysis for MOTIF BIO PLC/S
Headlines about MTFB stock have been trending positive on Saturday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MOTIF BIO PLC/S earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out...
Associated PressFeb 18